Key factors
sym | AIMT |
exch | US |
MCap | 2.257B |
Beta | 1.740 |
EPS | -3.72 |
Div date | 0000-00-00 |
Yesterday
sym | AIMT |
exch | US |
50 Day MA | 34.34 |
200 Day MA | 20.40 |
52 Week High | 37.0 |
52 Week Low | 10.09 |
Target Price | 31.28 |
Market Cap Mln | 2257.37 |
Share statistics
Shares Outstanding | 65.45M |
Shares Float | 49.00M |
Percent Institutions | 82.84 |
PercentInsiders | 20.85 |
SharesShort | 4179.5K |
Short Ratio | 0.99 |
Shares Short Prior Month | 6737.53K |
Short Percent | 9.030 |
Short Percent Float | 9.030 |
Short Percent Outstanding | 5.999 |
Income
Revenue TTM | 575.0K |
Revenue Per Share TTM | 0.009 |
EBITDA | -227.0M |
Diluted Eps TTM | -4.49 |
earning
Operating Margin TTM | -491.9 |
PEGRatio | 0.16 |
EPS Estimate Current Year | -4.23 |
EPS Estimate Next Year | -2.96 |
Earnings Share | -3.72 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Revenue | 3628.88 |
Book Value /share | 2.748 |
Price Book MRQ | 12.55 |
Price Sales TTM | 3832.47 |
ReturnOnAssetsTTM | -0.53 |
ReturnOnEquityTTM | -1.49 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US00900T1079 |
CIK | 0001631650 |
Code | AIMT |
CUSIP | 00900T107 |
Employer Id Number | 45-2748244 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2020-10-25 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 339.0 |
IPODate | 2015 |
International Domestic | Domestic |
MostRecent Quarter | 2020-06-30 |
Contact
Name | Aimmune Therapeutics, Inc |
Address | 8000 Marina Boulevard, Brisbane, CA, United States, 94005-1884 |
Country Name | USA |
Phone | 650 614 5220 |
Web URL | www.aimmune.com |
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. As of October 9, 2020, Aimmune Therapeutics, Inc. operates as a subsidiary of Société des Produits Nestlé S.A.